Eliciting preferences for prioritizing treatment of rare diseases: The role of opportunity costs and framing effects

PharmacoEconomics

Volumn 31, Issue 11, 2013, Pages 1051-1061

  Desser, Arna S ^a,b   Olsen, Jan Abel ^c   Grepperud, Sverre ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; HEALTH CARE COST; HUMAN; MEDICAL RESEARCH; NEOPLASM; NORWAY; PRIORITY JOURNAL; RARE DISEASE; RESOURCE ALLOCATION;

ADULT; AGED; CHOICE BEHAVIOR; DATA COLLECTION; DELIVERY OF HEALTH CARE; FEMALE; HEALTH CARE COSTS; HEALTH PRIORITIES; HUMANS; MALE; MIDDLE AGED; NORWAY; PUBLIC OPINION; RARE DISEASES; RESOURCE ALLOCATION;

EID: 84890346071     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0093-y     Document Type: Article

References (21)

1. Kahneman D, Ritov I, Schkade D. Economic preferences or attitude expressions? An analysis of dollar responses to public issues. J Risk Uncertain. 1999;19:203-35.
2. Tversky A, Kahneman D. The framing of decisions and the psychology of choice. Science. 1981;211:453-8.
3. Frisch D. Reasons for framing effects. Organ Behav Hum Decis Process. 1993;54:399-429.
4. American Educational Research Association, American Psychological Association, National Council on Measurement in Education, Joint Committee on Standards for Educational and Psychological Testing (US). Standards for educational and psychological testing. Washington, DC: American Educational Research Association; 2002.
5. Lloyd AJ. Threats to the estimation of benefit: are preference elicitation methods accurate? Health Econ. 2003;12:393-402.
6. McNeil BJ, Pauker SG, Sox HC, Tversky A. On the elicitation of preferences for alternative therapies. N Engl J Med. 1982;27(306):1259-62.
7. Kressel LM, Chapman GB. The default effect in end-of-life medical treatment preferences. Med Decis Mak. 2007;1(27):299-310.
8. Olsen JA, Donaldson C, Pereira J. The insensitivity of 'willingness-to-pay' to the size of the good: new evidence for health care. J Econ Psychol. 2004;25:445-60.
9. Goldberg I, Roosen J. Scope insensitivity in health risk reduction studies: a comparison of choice experiments and the contingent valuation method for valuing safer food. J Risk Uncertain. 2007;34:123-44.
10. McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ. 2005;331:1016-9.
11. US Food and Drug Administration. Orphan drug act of 1983 (as amended). 1983. http://www.fda.gov/regulatoryinformation/legislation/ federalfooddrugandcosmeticactfdcact/significantamendmentstothefdcact/ orphandrugact/default.htm. Accessed 3 July 2013.
12. European Parliament and Council. Regulation (EC) No. 141/2000 on orphan medicinal products [Internet]. 1999. http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri=CELEX:32000R0141:EN:NOT.
13. Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM. 2005;98:829-36.
14. Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23:36-42.
15. Desser AS, Gyrd-Hansen D, Olsen JA, Grepperud S, Kristiansen IS. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. BMJ. 2010;341:c4715.
16. Bardo JW, Yeager SJ, Klingsporn MJ. Preliminary assessment of format-specific central tendency and leniency error in summated rating scales. Percept Mot Skills. 1982;54:227-34.
17. Aguilar P, Brussino S, Fernández-Dols J-M. Psychological distance increases uncompromising consequentialism. J Exp Soc Psychol. 2013;49:449-52.
18. Olsen JA, Richardson J. Preferences for the normative basis of health care priority setting: some evidence from two countries. Health Econ. 2013;22:480-5.
19. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
20. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ. 2010;13:295-301.
21. Kahneman D, Knetsch JL. Valuing public goods: the purchase of moral satisfaction. J Env Econ Manag. 1992;22:57-70.